Ultragenyx Pharmaceutical CEO and leadership

Emil Kakkis (born 1960) is an American medical geneticist known for his work to develop treatments for ultra rare disorders. He is the President and Founder of the Kakkis Everylife Foundation for Rare Disease and Chief Executive Officer and President at Ultragenyx Pharmaceutical Inc.

Camille provides strategic leadership to the clinical development and translational research programs, and oversees Medical Affairs, Global Clinical Development, Clinical Operations and Drug Safety/Pharmacovigilance at Ultragenyx. Camille was an Assistant Professor of Medicine at Duke University Medical Center and member of the Duke Comprehensive Cancer Center, where she also had completed her residency in internal medicine and fellowship training in hematology and medical oncology. Camille received her degree in Honors Chemistry from Harvard University, an M.D. degree from Harvard Medical School and an M.S. degree in Biophysics from the Massachusetts Institute of Technology. Camille is a strategic thinker who has extensive hands-on experience developing new medicines for rare diseases and has helped build successful development organizations. Throughout her career, she has been highly regarded as a dedicated, patient-focused clinician and leader.

Erik Harris is the Executive Vice President & Chief Commercial Officer at Ultragenyx Pharmaceutical Inc.

John Pinion has over 25 years of global experience providing executive leadership and expertise in engineering, quality, manufacturing management of biologic, pharmaceutical and device operations across Asia, Europe and the Americas. He joined Ultragenyx in July 2015 and currently holds the role of EVP, Translational Sciences and Chief Quality Operations Officer. Mr. Pinion provides leadership for Ultragenyx’s translational sciences functions to include Pharmacology and Toxicology, Research and Bioanalytical Development, as well as GxP Quality and Compliance, Validation, and CMC Analytical Development and QC.

Mr. Thomas Kassberg joined Ultragenyx in November 2011. He is responsible for leading the company’s business development and corporate strategic planning activities, as well as the human resources and legal affairs functions. Mr. Kassberg brings more than twenty years of experience in the pharmaceutical and biotechnology industries. Prior to joining Ultragenyx, Mr. Kassberg worked as an independent consultant in Corporate Development and Business Strategy and consulted with a number of companies, including Corium International, Inc. and Rib-X Pharmaceuticals, Inc. Before becoming a consultant, Mr. Kassberg worked at Proteolix, Inc., where he served as Executive Vice President of Corporate Development, overseeing business development, corporate strategic planning and legal affairs. Prior to Proteolix, Mr. Kassberg served as Senior Vice President of Corporate Development and Commercial Operations at InterMune, Inc. At InterMune, he oversaw the commercial team responsible for in-line sales of Actimmune® and pre-launch planning for late-stage products. Mr. Kassberg was also a co-founder of Plexxikon, where he served as Vice President, Business and Corporate Development. In this role, he helped to establish the company's initial operations in addition to leading the company's corporate development activities. Prior to Plexxikon, Mr. Kassberg served as the Senior Director of Business Development and Corporate Licensing at SUGEN until the company's acquisition by Pharmacia.

Emil Kakkis (born 1960) is an American medical geneticist known for his work to develop treatments for ultra rare disorders. He is the President and Founder of the Kakkis Everylife Foundation for Rare Disease and Chief Executive Officer and President at Ultragenyx Pharmaceutical Inc.

Emil Kakkis (born 1960) is an American medical geneticist known for his work to develop treatments for ultra rare disorders. He is the President and Founder of the Kakkis Everylife Foundation for Rare Disease and Chief Executive Officer and President at Ultragenyx Pharmaceutical Inc.